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Abstract 
We present a very rare case of cerebellar metastasis of unknown origin, in which a primary 
lung adenocarcinoma was diagnosed by pathological examination of a cerebellar metastatic 
tumor, using immunohistochemical markers and epidermal growth factor receptor (EGFR) 
mutation of primary lung cancer. A 69-year-old woman was admitted to our hospital 
because of a hemorrhagic cerebellar tumor and multiple small brain tumors. She underwent 
cerebellar tumor resection. On pathological examination, the tumor was diagnosed as 
adenocarcinoma. However, the primary tumor site was unidentifiable even with several 
imaging inspections. On immunohistochemical analysis, the resected tumor was positive for 
napsin A and thyroid transcription factor-1. In addition, an EGFR mutation was detected in 
the tumor. Therefore, primary lung cancer was diagnosed and the patient was started on 
gefitinib (250 mg/day) therapy. 
 
Introduction 
Cerebral metastases of unknown origin are most frequently reported in association 
with primary lung cancer [1]. However, we could not find any reports in the literature 
in which the primary site was not detected within the lung fields. 
The prognosis of cancer of unknown origin is poor, with median survival times of 6–
12 months, and the advantage of chemotherapy over best supportive care remains 
unclear [2]. We present a very unique case of cerebellar metastasis of unknown origin,  
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in which primary lung adenocarcinoma was diagnosed by pathological examination of 
the cerebellar metastatic tumor. Moreover, the tumor was successfully treated with 
gefitinib. 
Case Presentation 
A 69-year-old woman was admitted to our hospital because of dizziness. Brain CT and MRI 
revealed a cerebellar tumor with hemorrhage, as well as multiple small brain tumors (fig. 1a, b). The 
cerebellar tumor was resected because of the hemorrhage, while the other tumors were treated using 
Gamma-Knife radiosurgery. Adenocarcinoma was strongly suspected on pathological examination 
(fig. 2a); however, the primary tumor site was unidentifiable. Serum carcinoembryonic antigen (CEA) 
and sialyl Lewis X antigen (SLX) levels were 129.9 ng/ml and 150 U/ml, respectively. Other tumor 
markers were within the reference range. Malignancy was not detected in the mammary glands, or in 
gynecological or gastroenterological areas. Chest CT revealed enlarged submandibular (only the right 
side), infraclavicular, and subcarinal lymph nodes (fig. 3a–c). Fluorodeoxyglucose (FDG) positron 
emission tomography revealed high FDG uptake in these lymph nodes (maximal standardized uptake 
values of 3.8, 8.2, and 10.2, respectively; fig. 3g). The resected tumor was positive for napsin A and 
thyroid transcription factor-1 (TTF-1) (fig. 2b); an epidermal growth factor receptor (EGFR) exon 19 
deletion mutation was also detected. These findings led us to strongly suspect lung adenocarcinoma 
(cTxN3M1b, stage IV). Thus, gefitinib (250 mg/day) treatment was initiated. 
On day 19 of the therapy, chest CT revealed 60% shrinkage in lymph node volume (fig. 3d–f), 
particularly in the subcarinal lymph nodes. On day 46, serum CEA and SLX levels were 11.6 ng/ml and 
29 U/ml, respectively. 
Discussion 
We successfully diagnosed a very rare case of lung adenocarcinoma with associated 
cerebellar metastasis of an unidentifiable primary site. Moreover, the patient 
immediately responded to gefitinib therapy. 
Napsin A and TTF-1 are useful immunohistochemical markers for primary lung 
cancer in cases where the primary site is unknown [3]. TTF-1 and napsin A typically 
stain positive in cases of lung and thyroid cancers [3] and renal cell carcinoma, 
respectively [4]. However, the use of napsin A and TTF-1 together is reportedly more 
beneficial in diagnosing primary lung adenocarcinoma [5]; hence, we arrived at a 
diagnosis of lung adenocarcinoma although the primary site was initially unknown. 
EGFR mutation is a specific genetic mutation of lung cancer [6]. We were thus 
convinced that the primary tumor site was the lung. 
Our case is unique because the cerebellar tumor was EGFR mutation positive, 
prompting the initiation of gefitinib therapy. Because gefitinib is effective in treating 
brain metastases of lung cancer with EGFR mutation [7], brain metastases may have 
been controlled in this case. The volumes of target lesions were reduced. This case may 
offer some useful insights concerning treatment of cerebral metastases of unknown 
origin. 
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Fig. 1. a Brain CT showing cerebral tumor with hemorrhage. b T2-weighted MRI image of the brain. 
 
 
 
Fig. 2. Microscopic appearance of the cerebellar tumor specimen. a Tumor cells showing papillary and 
ductal arrangement (H&E staining). b Tumor cell nuclei and cytoplasm stained with adenocarcinoma 
cocktail antibodies comprising TTF-1 and napsin A antibodies. 
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Fig. 3.  Chest CT on admission (a–c) and on day 19 (d–f) of the chemotherapy course. a, d Right 
submandibular lymph node (arrows). b, e Right infraclavicular lymph node (arrows). c, f Subcarinal 
lymph node (arrows). g FDG positron emission tomography highlighting the above-mentioned lymph 
nodes (arrows) on admission. 
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